Steroid Sulfatase Inhibitors: Therapeutic Applications and Development
May 2003
in “
Expert Opinion on Therapeutic Patents
”
Studysummary This review examines patents and publications on steroid sulfatase inhibitors since 1999 and reports no new clinical results, highlighting their potential for treating estrogen- and androgen-driven conditions.
Our plain-language summary. Not medical advice or a treatment recommendation. Consult a qualified healthcare professional before changing treatment. Full disclaimer
The 2003 document reviewed the role and potential therapeutic applications of Steroid Sulfatase (STS) inhibitors in various diseases, including hormone-dependent disorders like cancers, androgenic alopecia, and acne. STS inhibitors were seen as promising for treating these conditions by reducing local hormone production. The most advanced preclinical development of STS inhibitors was for breast cancer, with 667COUMATE identified as a candidate for clinical trials. The document also discussed the design of new inhibitors, considering potential estrogenicity and chemical stability. However, the document did not provide specific numbers of people involved in the studies, limiting the strength of the conclusions.
